From Russia (with love?) [RSABE / ABEL]

posted by PharmCat  – Russia, 2019-12-04 16:16 (1209 d 23:28 ago) – Posting: # 20924
Views: 5,664

Hello Helmut!

IMHO, main points:

1. Basic words. Review article.
2. ABEL/RSABE - all have TIE inflation.
3. Biggest inflation when CVintra = 25—30%.
4. EMA aproach better than FDA.


When you are planning bioequivalence trial better look at EMA guidelines, rather than FDA. We know that all approaches have TIE inflation.

I think this is primarily a message to regulatory experts.

Complete thread:

UA Flag
 Admin contact
22,557 posts in 4,724 threads, 1,607 registered users;
20 visitors (0 registered, 20 guests [including 9 identified bots]).
Forum time: 16:45 CEST (Europe/Vienna)

Science is wonderfully equipped to answer the question “How?”
but it gets terribly confused when you ask the question “Why?”    Erwin Chargaff

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz